30.41
  Price6.89%   -2.25
(Pre-market: 30.46 +0.0500 +0.16%)
Nov-30-21 04:20AM Fennec (FENC) Gets CRL From FDA for Pedmark, Stock DownZacks Investment Research
11:30AM Blueprint Medicines (BPMC) Set to Acquire Lengo TherapeuticsZacks Investment Research
Nov-30-21 11:18AM BioCryst (BCRX) Begins Enrollment in PNH Study on BCX9930Zacks Investment Research
Nov-25-21 10:56AM Selecta (SELB) Down on FDA's Clinical Hold on Phase I/II StudyZacks Investment Research
Nov-23-21 12:01PM CRISPR's (CRSP) CAR-T Cell Therapy Gets FDA's RMAT DesignationZacks Investment Research
11:52AM Deciphera (DCPH) Gets EU Nod for Qinlock in Fourth-Line GISTZacks Investment Research
Nov-22-21 11:23AM BioMarin's (BMRN) Dwarfism Drug Gets FDA's Nod, Stock UpZacks Investment Research
Nov-20-21 06:40AM Ocugen Stock: Bull vs. BearThe Motley Fool
Nov-19-21 10:03AM Novo Nordisk (NVO) Set to Acquire Dicerna for $3.3 BillionZacks Investment Research
Nov-16-21 09:08AM Coherus' (CHRS) Toripalimab Gets Orphan Drug Tag for Rare CancerZacks Investment Research
Nov-15-21 11:32AM Horizon (HZNP) Gets Positive CHMP Opinion for Uplizna in NMOSDZacks Investment Research
11:20AM Amgen's (AMGN) KRAS Inhibitor Gets CHMP Nod for Lung CancerZacks Investment Research
Nov-09-21 11:00AM Editas (EDIT) Q3 Earnings Beat Estimates, Revenues Fall Y/YZacks Investment Research
Nov-08-21 04:00AM Editas Medicine, Inc (EDIT) Q3 2021 Earnings Call TranscriptThe Motley Fool
12:52PM Why Editas Medicine Stock Is Jumping TodayThe Motley Fool
Nov-08-21 08:25AM Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research
08:24AM The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And MoreBenzinga
Nov-05-21 10:09AM Biotech Stocks' Q3 Earnings on Nov 8: VTRS, EDIT & MoreZacks Investment Research
Nov-04-21 09:02AM Editas Medicine to Present Data Demonstrating Progress Towards Transformative Gene Editing Medicines for the Treatment of Hemoglobinopathies and Cancer at the ASH Annual Meeting and ExpositionGlobeNewswire Inc.
Nov-02-21 10:02AM Editas (EDIT) to Report Q3 Earnings: What's in the Cards?Zacks Investment Research
Sep-26-21 07:04AM Wall Street Breakfast: The Week AheadSeeking Alpha
Sep-23-21 05:55AM Why Cathie Wood Is Buying 2 Gene-Editing Stocks but Selling AnotherThe Motley Fool
05:52AM Buying This Beaten-Down ETF Could Double Your Money Over the Next 5 YearsThe Motley Fool
Sep-09-21 12:37PM 3 Red-Hot Healthcare Stocks to Buy in SeptemberThe Motley Fool
Sep-03-21 11:31AM Why Is Editas (EDIT) Up 33.8% Since Last Earnings Report?Zacks Investment Research
Aug-31-21 09:40AM Could CRISPR Therapeutics Stock Help You Retire a Millionaire?The Motley Fool
Aug-30-21 11:02AM Global Blood (GBT) Thrives on Oxbryta, Overdependence a WoeZacks Investment Research
Aug-27-21 06:55AM The 3 Best Biotech Stocks to Buy Right NowThe Motley Fool
Aug-24-21 09:15AM NASDAQ Jumps Over 2.5% in 2 Days to Close at Record HighZacks Investment Research
Aug-23-21 09:15AM NASDAQ Jumps Over 2.5% in 2 Days to Close at Record High Investing.com
Aug-20-21 04:20AM Editas Medicine Presents Data on New SLEEK Gene Editing Technology at Cold Spring Harbor Laboratory’s Genome Engineering: CRISPR Frontiers MeetingGlobeNewswire Inc.
Aug-17-21 10:21AM Editas (EDIT) Up More Than 70% in Past 3 Months: Here's WhyZacks Investment Research
Aug-14-21 08:00AM How Are Genomics ETFs Responding to Q2 Earnings?Zacks Investment Research
Aug-12-21 05:52AM Will Moderna Buy Editas Medicine to Jump Into Gene Editing?The Motley Fool
Aug-09-21 06:05AM Why Editas Medicine Beat the Market on MondayThe Motley Fool
Aug-06-21 09:15AM S&P, NASDAQ Set New Highs While Waiting for Jobs ReportZacks Investment Research
Aug-05-21 12:43PM Editas (EDIT) Q2 Earnings Beat Estimates, Revenues Fall Y/YZacks Investment Research
09:15AM S&P Off Record High, Dow Down 300 Points as Jobs Data BeginsZacks Investment Research
Aug-04-21 05:30AM Editas Medicine, inc (EDIT) Q2 2021 Earnings Call TranscriptThe Motley Fool
08:15AM Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research
Aug-02-21 09:29AM Editas (EDIT) to Report Q2 Earnings: What's in the Cards?Zacks Investment Research
Jul-30-21 05:50AM Editas Medicine (EDIT) Stock Moves -0.1%: What You Should KnowZacks Investment Research
Jul-29-21 09:00AM Editas Medicine and IDT Announce Publication in Nature Communications of Research Data Supporting the Use of Optimized AsCas12a Nuclease Variant, Alt-R A.s. Cas12a (Cpf1) Ultra, in Researching the Potential of Gene-Edited Cell MedicinesGlobeNewswire Inc.
Jul-27-21 12:45PM 3 Reasons Caribou Biosciences Could Be the Best Gene-Editing Stock for Your PortfolioThe Motley Fool
Jul-23-21 07:01AM 5 Mid-Cap Healthcare Stocks You'll Want on Your Radar for the 2nd Half of 2021The Motley Fool
Jul-21-21 11:49AM Alzheimer's Approval, COVID-19 Vaccines Put Spotlight On Biotech Sector, But What's Next?Benzinga
Jul-16-21 11:02AM Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This WeekThe Motley Fool
Jul-15-21 08:19AM After Game-Changing Clinical Trial Results, These 2 Cathie Wood Stocks Are ExplodingThe Motley Fool
Jul-12-21 03:12AM WHO Issues Framework For Governance For Gene Editing TechnologiesBenzinga
Jul-10-21 05:19AM Is It Too Late to Buy Intellia Therapeutics?The Motley Fool
Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. It develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. The company also develops other therapies for eye diseases, such as Herpes Simplex Virus 1 that causes lifelong infections primarily leading to ocular and oral disease; and Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss. In addition, it develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited for the research and development of medicines for ocular diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Cap:    |  Volume (24h):